ZM 012
Alternative Names: ZM-012Latest Information Update: 03 Aug 2022
At a glance
- Originator Zumutor Biologics
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Natural killer cell receptor modulators; Neoplasm antigen stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Lymphoma; Unspecified
Most Recent Events
- 21 Jul 2022 Preclinical trials in Lymphoma in USA (Parenteral) (Zumutor Biologics pipeline, July 2022)
- 21 Jul 2022 Preclinical trials in Unspecified in USA (Parenteral) (Zumutor Biologics pipeline, July 2022)